What are the common signs and symptoms associated with subdermal contraceptive implants in female patients of reproductive age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Signs and Symptoms of Subdermal Contraceptive Implants

The most common signs and symptoms of subdermal contraceptive implants are menstrual bleeding changes (affecting up to 80% of users), including amenorrhea (22%), infrequent bleeding (34%), frequent bleeding (7%), and prolonged bleeding (18%), along with systemic effects such as weight gain (55%), acne, breast tenderness, and headache. 1, 2, 3

Menstrual Bleeding Pattern Changes

Expected Bleeding Irregularities

  • Amenorrhea occurs in approximately 22% of users and is generally not harmful, requiring only reassurance rather than treatment 1, 4, 3
  • Infrequent bleeding or spotting affects about 34% of women throughout implant use 5, 3
  • Frequent bleeding occurs in 6.7% of users 3
  • Prolonged bleeding affects 17.7% of users 3
  • Unscheduled spotting or light bleeding is most common during the first year and typically decreases with continued use 1, 5

Predictive Pattern

  • The bleeding pattern experienced during the first three months broadly predicts future patterns for most women 3
  • Women with favorable bleeding patterns in the initial phase tend to continue with this pattern throughout the first two years 3
  • Women with unfavorable initial patterns have at least a 50% chance that the pattern will improve over time 3

Systemic Adverse Effects

Common Symptoms

  • Weight gain is the most frequently reported systemic side effect, affecting approximately 55% of users 2, 6, 7
  • Acne is frequently reported 2, 7
  • Breast tenderness is commonly experienced 2
  • Headache occurs in a significant proportion of users 7
  • Dizziness and mood disturbances may occur 7
  • Nausea and lower abdominal pain are possible 7
  • Hair loss and loss of libido have been reported 7

Beneficial Effects

  • Approximately 77% of women with baseline dysmenorrhea experience complete resolution of menstrual pain symptoms 3

Local Insertion Site Effects

  • Pain at the implant site may occur 7
  • Neuropathy has been reported in rare cases 7
  • There is a small risk of pelvic infection limited to the first 20-21 days after insertion 2

Critical Clinical Pitfalls to Avoid

When Bleeding Changes Occur

  • Always rule out pregnancy if a woman's regular bleeding pattern changes abruptly to amenorrhea 4
  • Systematically evaluate for pregnancy, medication interactions, sexually transmitted diseases, and new pathologic uterine conditions (polyps, fibroids) before attributing all bleeding to the implant 5
  • Consider screening for STIs, particularly in adolescents, when unscheduled bleeding occurs 2

Counseling Importance

  • Provide comprehensive pre-insertion counseling about expected bleeding patterns to reduce discontinuation rates 1, 2, 3
  • Explain that bleeding changes are generally not harmful and may or may not decrease with continued use 1, 5
  • Advise women to return at any time to discuss side effects or if they want to change methods 1

Discontinuation Rates

  • Only 11.3% of patients discontinue due to bleeding irregularities, mainly because of prolonged flow and frequent irregular bleeding 3
  • Approximately 9% of women stop using implants during the first year, with menstrual problems being the main reason 8
  • Despite experiencing side effects, most women remove the implant only when it reaches the end of its contraceptive duration (43%) 6

Follow-Up Recommendations

  • No routine follow-up visit is required after insertion 1
  • At routine visits, assess satisfaction with the method, any concerns about use, and changes in health status that would affect appropriateness of continued use 1
  • Consider assessing weight changes and counseling women concerned about perceived weight gain associated with their method 1

References

Guideline

Mirena Adverse Drug Reactions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

The effects of Implanon on menstrual bleeding patterns.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2008

Guideline

Manejo de Amenorrea Secundaria en Pacientes con Implante Subdérmico

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Vaginal Spotting After One Year of Implanon Use

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Subdermal contraceptive implants.

The Journal of steroid biochemistry and molecular biology, 1995

Related Questions

Why do I have bleeding episodes twice a month while using the Nexplanon (etonogestrel) implant?
Is it common to not get a period when using a birth control implant, such as Nexplanon (etonogestrel)?
Can I experience irregular periods while on Oral Contraceptive Pills (OCPs)?
How should menorrhagia be managed in a patient using the Implanon (levonorgestrel) contraceptive implant?
Can Nexplanon (etonogestrel subdermal implant) cause heavy menstrual bleeding?
Do N-acetylcysteine (NAC) and memantine increase dopamine levels in patients, particularly in geriatric patients with dementia or psychiatric disorders?
How to manage a patient with biliary ectasia, distal common bile duct stricture, and pneumobilia following an Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure?
What are the pros and cons of using N-acetylcysteine (NAC) versus memantine in treating a patient with obsessive-compulsive disorder (OCD), attention deficit hyperactivity disorder (ADHD), sexual dysfunction, and fatigue?
What are the recommendations of the European Association of Urology (EAU) guidelines 2026 for managing urological diseases, such as prostate cancer, bladder cancer, kidney stones, and urinary tract infections?
Can N-acetylcysteine (NAC) be taken with stimulants in a patient with a complex psychiatric history, currently on Qelbree (viloxazine), sertraline, and guanfacine Extended Release (ER)?
What should be done for a relative who got bitten by a greater bandicoot rat and didn't receive any rabies vaccine, it's been some time since the incident?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.